Phase II trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone]-rituximab augmented with granulocyte-macrophage colony stimulating factor (GM-CSF [sargramostim]) in patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Sargramostim; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2011 Planned end date changed from 1 Dec 2008 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.